Bobbie Rimel

7PUBLICATIONS
32CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Women's studies (incl. girls' studies)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 13, 2026
Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0.

|Oct 10, 2025
The Impact of JAK1 Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial Cancer.

Erica V Carballo, Paula Gonzalez-Ericsson, Brian D Lehmann

|Mar 11, 2025
The missing data: A review of gender and sex disparities in research.

Hannah C Karpel, Linda M Zambrano Guevara, B J Rimel

|Jul 04, 2024
Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study.

Bobbie Rimel, Tirza Areli Calderón Boyle, Sara Burns

|Dec 21, 2023
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.

Bobbie J Rimel, Danielle Enserro, David P Bender

|Oct 14, 2022
Current gaps and opportunities in screening, prevention, and treatment of cervical cancer.

Bobbie J Rimel, Charles A Kunos, Nikeya Macioce

Pageof 2

Frequent Collaborators

1 joint publications

Therica M Miller

1 joint publications

Lorna Kwan

1 joint publications

Hannah C Karpel

1 joint publications

Linda M Zambrano Guevara